Provided by Tiger Trade Technology Pte. Ltd.

Bicara Therapeutics

17.50
+0.24001.39%
Post-market: 17.500.00000.00%19:30 EDT
Volume:715.97K
Turnover:12.56M
Market Cap:1.16B
PE:-5.63
High:17.82
Open:17.19
Low:16.88
Close:17.26
52wk High:30.99
52wk Low:13.70
Shares:66.17M
Float Shares:36.76M
Volume Ratio:0.79
T/O Rate:1.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1097
EPS(LYR):-2.5230
ROE:-41.01%
ROA:-26.14%
PB:2.47
PE(LYR):-6.94

Loading ...

Bicara says ficerafusp alfa plus pembrolizumab shows 31% three-year survival in Phase 1b HNSCC

Reuters
·
May 22

Bicara Therapeutics management to meet with Cantor

TIPRANKS
·
May 22

Bicara CEO Claire Mazumdar sells $300,000 common shares

Reuters
·
May 21

Bicara Therapeutics Highlights Momentum in Earnings Call

TIPRANKS
·
May 20

Bicara Therapeutics’ Earnings Call Highlights Ficera Momentum

TIPRANKS
·
May 19

Bicara President, COO Ryan Cohlhepp sells 12,500 shares for $253,649.38

Reuters
·
May 19

Bicara grants new CCO option for 282,240 shares at $22.58 each

Reuters
·
May 13

Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 13

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 13

Bicara Therapeutics files initial beneficial ownership statement for CMO William Schelman

Reuters
·
May 13

Bicara Therapeutics Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
May 13

Bicara Therapeutics Inc. (BCAX) Gets a Buy from Morgan Stanley

TIPRANKS
·
May 12

Bicara Therapeutics Initiated at Buy by Guggenheim

Dow Jones
·
May 12

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 12

Bicara Therapeutics posts corporate deck spotlighting ficerafusp alfa for HPV-negative head and neck cancer

Reuters
·
May 11

Stock Track | Bicara Therapeutics Plunges 11.43% in Pre-Market After Wider-Than-Expected Q1 Loss

Stock Track
·
May 11

Bicara Therapeutics Q1 Loss Widens

MT Newswires Live
·
May 11

Earnings Flash (BCAX) Bicara Therapeutics Posts Q1 Loss $0.93 a Share, vs. FactSet Est of $0.65 Loss

MT Newswires Live
·
May 11

Bicara Therapeutics Q1 EPS $(0.93) Misses $(0.68) Estimate

Benzinga Earnings
·
May 11

Bicara Therapeutics Inc - Q1 Net Loss $56.2 Mln

THOMSON REUTERS
·
May 11